S-1/A: Onconetix Files Amendment for Common Stock Resale, Addressing Financial Risks and Strategic Shifts

Onconetix files an amendment to its registration statement for the resale of common stock, outlining its financial position, strategic shifts, and associated risks.

Summary

• Onconetix, a commercial-stage biotechnology company, has filed an amendment to its registration statement for the resale of 7,828,812 shares of common stock by selling stockholders.
• The company is focused on men's health and oncology, owning Proclarix (a prostate cancer diagnostic test) and ENTADFI (a BPH treatment).
• Onconetix has paused commercialization of ENTADFI and is considering strategic alternatives, including a potential sale of the ENTADFI assets.
• The company expects to generate revenue from Proclarix sales by 2025.
• Onconetix has a working capital deficit of approximately $11.4 million and an accumulated deficit of approximately $56.8 million as of December 31, 2023.
• The company needs to raise additional capital within the next 12 months to sustain operations.
• If stockholder approval is not obtained by January 1, 2025, the company may be obligated to cash settle the Series B Preferred Stock for approximately $41.3 million based on the stock price as of June 18, 2024.
• The company faces substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a mixed outlook with potential for future revenue generation but significant financial challenges and risks. The pause in ENTADFI commercialization and the need for additional capital raise concerns.

Positives

• Proclarix is approved for sale in the European Union and is expected to generate revenue by 2025.
• The company is focusing its efforts on commercializing Proclarix.
• Proclarix is included in the 2023 AUA/SUO clinical practice guideline.
• The company has engaged an investment advisor to assist with a potential sale or other transaction of the ENTADFI assets.

Negatives

• The company has a limited operating history and has incurred significant net losses since inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company owes a significant amount of money to Veru, which it may be unable to pay.
• The company is currently ineligible to file new short form registration statements on Form S-3, which may impair its ability to raise capital on favorable terms.
• The company has paused commercialization of ENTADFI.
• The company has a significant customer concentration, with a limited number of customers accounting for a large portion or all of its revenues.

Risks

• Sales of a substantial number of the company's securities in the public market could cause the price of its shares of Common Stock to fall.
• The company depends entirely on the success of a limited number of products.
• The company may not be able to successfully grow sales of ENTADFI in the U.S. market and Proclarix in the European markets.
• The company may not be able to gain and retain market acceptance for its products.
• The company may be unable to manage its manufacturing and supply chain effectively, which would harm its results of operations.
• The company may in the future have conflicts with its current or future partners or third-party providers that could delay or prevent the commercialization of its current products.
• Product liability lawsuits against the company could cause it to incur substantial liabilities and to limit commercialization of its products.
• Security threats to the company's information technology infrastructure and/or its physical buildings could expose it to liability and damage its reputation and business.
• The company will need to grow the size of its organization in the future, and it may experience difficulties in managing this growth.
• The company's future success depends on its ability to retain its executive officers and to attract, retain and motivate qualified personnel.
• Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent review of regulatory submissions in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
• The company may be adversely affected by natural disasters, pandemics, and other catastrophic events, and by man-made problems such as terrorism and acts of war, that could disrupt its business operations and its business continuity and disaster recovery plans may not adequately protect it from a serious disaster.
• The company's employees, independent contractors, principal investigators, consultants, and vendors engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
• Macroeconomic pressures in the markets in which the company operates, including, but not limited to, the current conflicts in Ukraine and the Middle East may alter the ways in which the company conducts its business operations and manages its financial capacities.
• The market price of the company's common stock has been extremely volatile and may continue to be highly volatile due to numerous circumstances beyond its control, and stockholders could lose all or part of their investment.
• The company may be subject to securities litigation, which is expensive and could divert its management's attention.
• The company may have violated Section 13(k) of the Exchange Act (implementing Section 402 of the Sarbanes-Oxley Act of 2002) and may be subject to sanctions as a result.
• If the company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.
• The company is an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies could make its common stock less attractive to investors.
• The company is subject to increased costs as a result of operating as a public company, and its management is required to devote substantial time to new compliance initiatives.
• If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about the company's business, its stock price and its trading volume could decline.
• The company's stock repurchase program may adversely affect its liquidity and cause fluctuations in its stock price.
• Failure in, or security breaches or incidents impacting, the company's information technology or storage systems could significantly disrupt its operations and its research and development efforts.
• The company's Amended and Restated Certificate of Incorporation and its Amended and Restated Bylaws and Delaware law may have anti-takeover effects that could discourage, delay, or prevent a change in control, which may cause its stock price to decline.
• The issuance or conversion of securities would result in significant dilution in the equity interest of existing shareholders and adversely affect the marketplace of the securities.
• The Committee on Foreign Investment in the United States (CFIUS) may delay, prevent or impose conditions on the Conversion.
• If the company fails to maintain an effective system of internal controls, it may not be able to accurately report its financial results or prevent fraud which could subject it to regulatory sanctions, harm its business and operating results and cause the trading price of its stock to decline.
• Our Amended and Restated Certificate of Incorporation requires, to the fullest extent permitted by law, that derivative actions brought in our name, actions against our directors, officers, other employees or stockholders for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholders counsel, which may have the effect of discouraging lawsuits against our directors, officers, other employees or stockholders.
• An active trading market for our common stock may not develop or be sustained.
• Our principal stockholders and management own a significant percentage of our capital stock and will be able to exert a controlling influence over our business affairs and matters submitted to stockholders for approval.
• There can be no assurance that we will be able to comply with the continued listing standards of Nasdaq.
• If our shares become subject to the penny stock rules, it would become more difficult to trade our shares.
• Future sales of our shares by existing stockholders could cause our stock price to decline.
• We may be subject to securities litigation, which is expensive and could divert our managements attention.
• We may have violated Section 13(k) of the Exchange Act (implementing Section 402 of the Sarbanes-Oxley Act of 2002) and may be subject to sanctions as a result.
• If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.
• We are an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies could make our common stock less attractive to investors.
• We are subject to increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.
• If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and our trading volume could decline.
• Our stock repurchase program may adversely affect our liquidity and cause fluctuations in our stock price.
• Failure in, or security breaches or incidents impacting, our information technology or storage systems could significantly disrupt our operations and our research and development efforts.
• Our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws and Delaware law may have anti-takeover effects that could discourage, delay, or prevent a change in control, which may cause our stock price to decline.
• We do not anticipate paying any cash dividends on our common stock in the foreseeable future and, as such, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.
• Environmental, social and governance matters may impact our business and reputation.
• A possible short squeeze due to a sudden increase in demand of our common stock that largely exceeds supply may lead to price volatility in our common stock.

Future Outlook

The company expects to generate revenue from Proclarix sales by 2025 and will need to raise additional capital to fund operations for the foreseeable future.

Industry Context

The announcement reflects a strategic shift towards men's health and oncology, aligning with growing market opportunities in these areas. The company faces competition from established pharmaceutical and diagnostic companies.

Comparison to Industry Standards

• Proclarix is subject to competition from other prostate cancer diagnostics and larger, well-established companies with substantially greater resources than us.
• ENTADFI is subject to competition from other BPH drugs and larger, well-established companies with substantially greater resources than us.
• Zydus Life Sciences recently received FDA approval for a combined finasteride-tadalafil (5 mg/5 mg) capsule, pursuant to the FDAs Competitive Generic Therapy Program, which was designed to enhance patient access to affordable medications by encouraging the development and commercialization of generic drugs in clinical areas with limited generic options for patients.

Management Changes

Legal Proceedings

• WraSer has advised the company that it does not believe that a Material Adverse Event occurred and has recently filed a plan of reorganization that indicates it may seek damages from the company due to the termination of the APA and MSA.

Related Party Transactions

• The company has entered into a subscription agreement with the PMX Investor, a 5% stockholder of the company as of December 31, 2023.
• The company issued a non-convertible debenture in the principal amount of $5.0 million to the PMX Investor, in connection with the Subscription Agreement.
• A former director of the company, who served on the company's Scientific Advisory Board until August 2023, serves on the Advisory Board for the Cincinnati Childrens Hospital Medical Center Innovation Fund, which is affiliated with CHMC. The company has an exclusive license agreement with CHMC.

Stakeholder Impact

• Shareholders may experience dilution and potential loss of investment due to the company's financial challenges and need for additional capital.
• Employees may be affected by cost reduction plans and strategic shifts.
• Customers and patients may experience changes in product availability and commercialization strategies.

Next Steps

• The company will focus its efforts on commercializing Proclarix.
• The company will explore strategic alternatives to monetize ENTADFI, such as a potential sale of the ENTADFI assets.
• The company will attempt to secure additional required funding through equity or debt financings if available.
• The company will seek stockholder approval for certain transactions involving the Companys Series B Preferred Stock.

Key Dates

Keywords

Onconetix, common stock, resale, securities, Proclarix, ENTADFI, financial position, risk factors, biotechnology, preferred stock, warrants, going concern, commercialization, acquisition, private placement, stockholders